BTAI stock forecast
Our latest prediction for BioXcel Therapeutics, Inc.'s stock price was made on the Aug. 16, 2019 when the stock price was at 9.15$.
In the short term (2weeks), BTAI's stock price should outperform the market by 3.42%. During that period the price should oscillate between -8.02% and +14.69%.
In the medium term (3months), BTAI's stock price should outperform the market by 3.56%. During that period the price should oscillate between -20.32% and +33.32%.Get email alerts
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.78$ per share.
The book value per share is 2.93$
Three months stock forecastAug. 16, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|